Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To our knowledge, this is the first research to explore the role of both YAP and TAZ in HCC hypoxic microenvironment in vitro and in vivo.
|
31146919 |
2019 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
RT-qPCR and western blot were used to assess YAP expression in HCC cell lines.
|
31337986 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The identification of the LATS1/2-YAP pathway as a target of myricetin may help with the design of novel strategies for human HCC prevention and therapy.
|
30999669 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggested that the CENPK-YAP1-EMT axis plays a critical role in regulating HCC malignant progression, indicating the role of this axis as a potential therapeutic target for HCC.
|
30774374 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This CD36-Nogo-B-YAP pathway consequently reprograms oxLDL metabolism and induces carcinogenetic signaling for NAFLD-associated HCCs.
|
31358770 |
2019 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study investigated the role of miR-424-5p in regulating YAP1 expression and affecting hepatoma cell proliferation and apoptosis.
|
30676784 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CBX2 Regulates Proliferation and Apoptosis via the Phosphorylation of YAP in Hepatocellular Carcinoma.
|
31258779 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
|
29698666 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of YAP1 in adult mouse liver leads to hepatomegaly and can cause hepatocellular carcinoma; while the loss of function studies reveal its importance in regulating cholangiocyte development.
|
29627454 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, we showed that MCP1 is a direct transcription target of YAP in hepatocytes and identified a strong gene expression correlation between YAP targets and MCP-1 in human HCCs.
|
28866620 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the established nomogram based on the independent risk factors may become an important part of HCC prediction system and YAP/VGLL4 balance may be a potential therapeutic target in future.
|
29950605 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The microRNA-590-5p/YAP axis plays an important role in the chemotherapeutic resistance of HCC cells, suggesting new adjuvant chemotherapeutic directions in HCC.
|
30111512 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A high level of YAP/ TAZ expression was associated with a high level of IRS2 expression in human hepatocellular carcinoma (HCC).
|
29400692 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results reveal a novel positive feedback loop involving CD44S and YAP1, in which CD44S functions as both an upstream regulator and a downstream effector of YAP1 in HCC.
|
29649630 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma.
|
30361504 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
AXIN1-mutated HCCs occur independently of the Wnt/β-catenin pathway and involve Notch and YAP pathways.
|
29525529 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this paper, we showed that COX-2 overexpression in HCC cell lines resulted in increased levels of YAP mRNA, protein, and its target genes.
|
29505957 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the EGFR-PI3K-PDK1 pathway could activate the YAP signaling, and the activated EGFR signaling could promote the HCC cell growth in a YAP-independent manner.
|
29449645 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
|
29698666 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Notably, this study confirmed that miR-195, YAP and their combination were valuable predictors for the prognosis of HCC patients.
|
29245938 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
For HCCs, a trend of poor progression-free survival for YAP1(+) HCCs was observed (39 ± 18 vs. 81 ± 5 months, mean ± SD, log rank p-value 0.205) CONCLUSIONS: YAP1 activation was more commonly found in CCAs than in pure HCCs.
|
28645247 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, plasmacytoma variant translocation 1 served as an endogenous sponge for miR-186-5p to reduce its inhibiting effect on yes-associated protein 1 and thus promoted the tumorigenesis of hepatocellular carcinoma.
|
28656879 |
2017 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we confirmed yes-associated protein 1 (YAP1) was up-regulated in HCC cells and tissues, and overexpression of YAP1 promoted HCC cell proliferation and migration.
|
29187885 |
2017 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Pearson's correlation coefficient analysis indicated WWC2 expression correlated inversely with nuclear YAP protein expression in HCC.
|
28815883 |
2017 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression and activation of YAP-1 in HCC T cells can induce immunosuppression by promoting Treg differentiation via transcriptional enhancement of TGFBR2.
|
28472799 |
2017 |